Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230. (scientific article)

Structural and biochemical characterization of Plasmodium falciparum 12 (Pf12) reveals a unique interdomain organization and the potential for an antiparallel arrangement with Pf41

Q27230051

Structure of the Plasmodium 6-cysteine s48/45 domain

Q27678432

Adhesion protein complexes of malaria gametocytes assemble following parasite transmission to the mosquito

Q27974518

Knowledge-based protein secondary structure assignment

Q29547838

Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases

Q29617578

Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity

Q30042993

A quantitative slot blot assay for host cell protein impurities in recombinant proteins expressed in E. coli

Q33222694

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

Q33350210

A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli

Q33485233

The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species

Q33892507

Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum

Q34015845

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

Q34043843

Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle

Q34341570

Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays

Q34618434

IgG1 protects against renal disease in a mouse model of cryoglobulinaemia

Q35127662

Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex

Q35132063

N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity

Q35138720

A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum

Q35138735

Pfs230: from malaria transmission-blocking vaccine candidate toward function

Q35548285

The Structure of Plasmodium falciparum Blood-Stage 6-Cys Protein Pf41 Reveals an Unexpected Intra-Domain Insertion Required for Pf12 Coordination

Q35790481

Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates

Q35925379

Analysis of the conformation and function of the Plasmodium falciparum merozoite proteins MTRAP and PTRAMP

Q35941001

Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer

Q35982771

Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains

Q36053524

Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice

Q36670217

Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders

Q36718066

High-resolution comparative modeling with RosettaCM.

Q37263048

Naturally acquired antibody responses to recombinant Pfs230 and Pfs48/45 transmission blocking vaccine candidates

Q39018502

Limited polymorphism in Plasmodium falciparum sexual-stage antigens

Q39304090

Transmission blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype dependent

Q39821154

Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230.

Q39830524

Target antigens of malaria transmission blocking immunity exist as a stable membrane bound complex

Q44027193

The 230-kDa gamete surface protein of plasmodium falciparum is also a target for transmission-blocking antibodies

Q44146561

Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing

Q44168384

Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production

Q44169388

Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes

Q44173322

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

Q46182948

Identification of additional members define a Plasmodium falciparum gene superfamily which includes Pfs48/45 and Pfs230.

Q47850151

Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid

Q47856385

Plasmodium falciparum: a comparison of the activity of Pfs230-specific antibodies in an assay of transmission-blocking immunity and specific competition ELISAs

Q47999189

Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris

Q48019028

Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum

Q48103837

Proteolysis of Plasmodium falciparum surface antigen, Pfs230, during gametogenesis

Q73613112

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

Plasmodium falciparum

Q311383

P304

page(s)

19913-19922

P577

publication date

2016-07-18

P1433

published in

Journal of Biological Chemistry

Q867727

P1476

title

Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.

P478

volume

291

Reverse relations

cites work (P2860)

Q92669430	A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system
Q47106697	Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium
Q40118467	An N-terminal Pfs230 domain produced in baculovirus as a biological active transmission-blocking vaccine candidate
Q92965786	Antibodies against Plasmodium falciparum malaria at the molecular level
Q64262577	Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice
Q96813794	Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230
Q33880789	Developing transmission-blocking strategies for malaria control
Q93099494	Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha
Q92234270	ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum
Q93056756	Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidate
Q28365035	Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate
Q56374576	Genetic approach towards a vaccine against malaria
Q62960064	Identification of domains within Pfs230 that elicit transmission blocking antibody responses
Q92001627	Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites
Q61448744	Low Levels of Human Antibodies to Gametocyte-Infected Erythrocytes Contrasts the PfEMP1-Dominant Response to Asexual Stages in Malaria
Q48021662	Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission
Q56362064	Malaria Vaccines: Recent Advances and New Horizons
Q90024117	Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity
Q96607419	Malaria vaccines since 2000: progress, priorities, products
Q59800434	Novel Strategies for Malaria Vaccine Design
Q91941697	Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230
Q64898220	Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum.
Q110697582	Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation
Q56337913	Progress toward a transmission-blocking vaccine against malaria
Q47251697	Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity
Q36165265	Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults
Q97692950	Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins
Q59923959	The Plasmodium yoelii microgamete surface antigen (PyMiGS) induces anti-malarial transmission blocking immunity that reduces microgamete motility/release from activated male gametocytes
Q58732770	The prevalence of submicroscopic Plasmodium falciparum gametocyte carriage and multiplicity of infection in children, pregnant women and adults in a low malaria transmission area in Southern Ghana
Q92954169	Transmission-Blocking Vaccines: Old Friends and New Prospects

P356	DOI	10.1074/JBC.M116.732305
P932	PMC publication ID	5025679
P698	PubMed publication ID	27432885